Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

inteRNAlizer

Financiado

Efficient, safe, and cost-efficient RNA delivery vehicles for hard-to-transfect...

Efficient, safe, and cost-efficient RNA delivery vehicles for hard-to-transfect pre-clinical and therapeutic cells. Human induced pluripotent stem cells (hIPSCs) have revolutionized the study of cell type-specific processes and the generation of organoids, tissues, and therapeutic cells for biomedical purposes. However, the genetic modificatio... ver más

31/05/2025

TUM

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

TECHNISCHE UNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-28

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

TUM

150.00K€ | Lider

Proyectos interesantes

EdiGenT New Prime Editing and non-viral delivery strategies for Gene... 4M€ Cerrado

Penphomet PEN photoporation for the genetic engineering of therapeutic... 2M€ Cerrado

NOVISTEM NOn-VIral gene modified STEM cell therapy 4M€ Cerrado

PGC2018-098626-B-I00 ANALISIS DEL PAPEL DE LAS ENZIMAS MODIFICANTES DEL RNA EN LA... 106K€ Cerrado

NANO-ENGINE A revolutionary cell programming platform based on the targe... 3M€ Cerrado

SCRIBE RNA-based gene writing in human cells 2M€ Cerrado

Últimas noticias

02-12-2024: AGENCIA-VALENCIANA-D... En las últimas 48 horas el Organismo AGENCIA VALENCIANA D... ha otorgado 1 concesiones

02-12-2024: CDTI En las últimas 48 horas el Organismo CDTI ha otorgado 4 concesiones

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2023-11-28
Fecha Fin: 2025-05-31

Líder del proyecto

TECHNISCHE UNIVERSITAET MUENCHEN

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Human induced pluripotent stem cells (hIPSCs) have revolutionized the study of cell type-specific processes and the generation of organoids, tissues, and therapeutic cells for biomedical purposes. However, the genetic modification of these cells, along with other difficult-to-transfect cells, poses a major challenge for performing high-throughput gene reporter and genetic perturbation assays and prevents us from fully exploiting the potential of hIPSCs. Existing gene delivery techniques, such as lentiviruses or lipid nanoparticles, suffer from limitations in precision, biosafety, efficacy, and high production costs. To overcome these limitations, our team has developed a novel approach called inteRNAlizers, which offers a genetically controlled cellular production process for non-viral RNA delivery systems. inteRNAlizers can enable transient gene expression and modular gene editing in virtually any cell type, including differentiated hIPSC and T cells. The method demonstrates high efficacy and cost efficiency while maintaining biosafety levels comparable to S1 standards. We aim to position inteRNAlizers as a promising alternative to lentiviruses and lipid nanoparticles, opening up new possibilities in gene delivery applications for preclinical research and therapeutic cell systems.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores